Research programme: MALT1 inhibitors - Schrodinger
Alternative Names: MALT1 program; SDGR3; SDGR3-MALT1Latest Information Update: 28 Jan 2025
At a glance
- Originator Schrodinger
- Class Antineoplastics; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mantle-cell lymphoma
- No development reported Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA (PO)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA (PO)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (PO)